Highlights

  • Acrux shares surged 60% on 28 May 2026, after the company expanded its licensing agreement for Lenzetto in the Australian market.
  • Acrux could receive up to AUD 5.4 million in milestone payments over two years.
  • Payments include upfront, regulatory and commercial milestones from partner Gedeon Richter Plc.
  • Lenzetto is already marketed in more than 40 countries globally.
  • The menopause hormone therapy product generated EUR 50 million in sales during 2025.
  • The Australian launch is expected to help address local shortages of menopause hormone therapy products.

Acrux Ltd (ASX:ACR) shares surged during afternoon trade on 28 May 2026 after the specialty pharmaceutical company announced an expanded licensing agreement for its menopause hormone therapy product Lenzetto in the Australian market.

The stock climbed 60% to AUD 0.016, making it one of the stronger movers on the ASX during the session. Despite the sharp rally, Acrux shares remain down approximately 20% over the past year.

Investor interest appeared to be driven by the financial implications of the amended agreement as well as the prospect of Lenzetto entering the Australian market at a time when the country continues to experience shortages of menopause hormone therapy (MHT) products.

The announcement also highlighted the growing commercial footprint of Lenzetto, which is already marketed internationally through long-term partner Gedeon Richter Plc.

Expanded Licensing Agreement Adds New Australian Opportunity

Acrux confirmed it had executed an amendment to its existing licensing agreement with pharmaceutical partner Gedeon Richter Plc covering the Australian market for Lenzetto.

Under the revised agreement, Acrux is expected to receive upfront payments alongside regulatory and commercial milestone payments linked to the product’s Australian rollout.

The company stated that total milestone payments could reach up to AUD 5.4 million within two years from launch.

While the detailed commercial terms remain confidential, investors appeared encouraged by the size of the potential milestone payments relative to Acrux’s current market valuation.

The company described the agreement as an important step toward making the locally developed Estradiol spray available to Australian women experiencing symptoms associated with menopause and oestrogen deficiency.

Lenzetto Already Established Internationally

One of the more significant aspects of the announcement was that Lenzetto is not an early-stage or unproven product.

The menopause hormone therapy treatment is already licensed to and marketed by Gedeon Richter in more than 40 countries worldwide.

According to Acrux, global sales of Lenzetto reached approximately EUR 50 million during 2025.

The product is a transdermal Estradiol spray designed to treat symptoms associated with oestrogen deficiency after menopause, including hot flushes.

Lenzetto uses Acrux’s proprietary Patchless Patch™ technology, which enables Estradiol delivery through a topical spray rather than conventional patches or oral therapies.

The company noted that the technology originated from research conducted at Monash University.

Investors may have viewed the established international sales performance as a positive indicator supporting the Australian market opportunity.

Australian Market Shortages Create Commercial Opportunity

The announcement also arrives against the backdrop of ongoing shortages in menopause hormone therapy products across Australia.

Acrux stated that the pending Australian launch of Lenzetto is expected to help address this Supply gap.

Management indicated that making the product available locally has been a strategic priority for the company.

Chief Executive Officer and Managing Director John Warmbrunn said the agreement expansion would provide benefits both for Australian patients and the company’s financial outlook.

According to Warmbrunn, Australian women suffering from oestrogen deficiency after menopause are expected to gain access to an additional treatment option through the amended arrangement with Richter.

The company also highlighted several practical characteristics of the therapy, including precise dosing, consistency and ease of use.

Product Development and Technical Affairs Director Felicia Colagrande said the launch would provide Australian women with a more discrete and convenient menopause hormone therapy option.

Financial Implications Draw Investor Attention

The potential AUD 5.4 million in milestone payments appeared to be one of the key drivers behind today’s share price reaction.

For a company of Acrux’s size, milestone-based licensing agreements can represent meaningful sources of non-dilutive funding.

The payments are expected to include upfront proceeds as well as regulatory and commercial milestones over the two years following launch.

Management suggested the additional funding may strengthen Acrux’s financial position as the company continues progressing its broader pipeline strategy.

Warmbrunn specifically referenced the company’s Female Testosterone product, noting that the incoming payments may support Acrux as it works toward bringing that therapy to market.

The agreement also reinforces the value of the company’s long-standing relationship with Gedeon Richter, a global pharmaceutical group focused on women’s healthcare and specialty medicines.

Who Is Gedeon Richter?

Gedeon Richter Plc is a Hungary-based pharmaceutical company founded in 1901 and operates one of Central Europe’s larger Research and Development hubs.

According to the announcement, Richter reported sales of EUR 2.3 billion in 2025 and held a Market Capitalisation of approximately EUR 4.8 billion.

The company focuses on areas including women’s healthcare, neuropsychiatry, biotechnology and general medicines.

Richter has already been commercialising Lenzetto internationally and now appears set to expand distribution into Australia under the amended licensing arrangement.

For Acrux, continuing to partner with a globally established pharmaceutical company may provide additional commercial support and market access capabilities.

Understanding Acrux’s Broader Business

Acrux is an Australian specialty pharmaceutical company focused on developing and commercialising topically applied drug products.

The company has more than two decades of experience in transdermal drug delivery technologies and has previously commercialised products internationally through licensing partnerships.

Its Patchless Patch™ technology platform has formed part of several product development programs over the years.

Acrux’s business strategy generally centres on partnering products with larger pharmaceutical companies capable of managing commercialisation and distribution across international markets.

The company continues to focus on women’s health opportunities alongside other specialty pharmaceutical developments.

Why the Market Reacted So Strongly

The scale of today’s share price move likely reflected several overlapping factors.

Firstly, the possibility of up to AUD 5.4 million in milestone payments represents a sizeable funding opportunity relative to Acrux’s current size.

Secondly, the agreement supports Australian commercialisation of a product that already has an established international sales track record.

Investors also appeared encouraged by the relevance of the product within a market currently facing shortages of menopause hormone therapy treatments.

In addition, the announcement reinforced the company’s ongoing relationship with a major international pharmaceutical partner, which may have further strengthened investor confidence in the commercial opportunity.

The combination of near-term financial benefits, existing product validation and a potentially favourable market environment appeared to contribute to the sharp upward movement in Acrux shares.

What Investors May Watch Next

Following today’s announcement, investors are likely to focus on regulatory progress and launch timing for Lenzetto in Australia.

Further details regarding milestone achievement timing and commercial rollout plans may also remain key areas of interest.

Market Participants may additionally watch whether Acrux can Leverage the incoming payments to support development of its broader pipeline, including its Female Testosterone product.

Sales performance in Australia following launch could also become an important indicator of the long-term commercial contribution from the expanded agreement.